SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "LAR1:lu ;srt2:(2005-2009);mspu:(article);spr:eng;pers:(Berntorp Erik)"

Sökning: LAR1:lu > (2005-2009) > Tidskriftsartikel > Engelska > Berntorp Erik

  • Resultat 1-10 av 48
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Al-Shanqeeti, A, et al. (författare)
  • Protein Z and protein Z-dependent protease inhibitor - Determinants of levels and risk of venous thrombosis
  • 2005
  • Ingår i: Thrombosis and Haemostasis. - F K Schattauer Verlag Gmbh. - 0340-6245. ; 93:3, s. 411-413
  • Tidskriftsartikel (refereegranskat)abstract
    • To assess the potential roles of protein Z (PZ) and protein Z-dependent protease inhibitor (ZPI) in venous thrombosis, their plasma levels were measured in 426 individuals with venous thrombosis and 471 control individuals participating in the Leiden Thrombophilia Study. A relationship between the level of PZ or ZPI and venous thrombosis was not detected in the overall case-control study. PZ and ZPI circulate as a complex and their plasma levels are interdependent. Both PZ and ZPI are increased with oral contraceptive use and reduced with oral anticoagulant therapy.
2.
  • Astermark, Jan, et al. (författare)
  • A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor.
  • 2007
  • Ingår i: Blood. - American Society of Hematology. - 1528-0020. ; 109:Sep 21, s. 546-551
  • Tidskriftsartikel (refereegranskat)abstract
    • The development of inhibitory antibodies to factor VIII is a serious complication of hemophilia. FEIBA (factor VIII inhibitor-bypassing activity), an activated prothrombin complex concentrate (aPCC), and NovoSeven, recombinant factor Vila (rFVIIa), are used as hemostatic bypassing agents in treating patients with inhibitors. The FENOC study was designed to test equivalence of the products in the treatment of ankle, knee, and elbow joint bleeding. A prospective, open-label, randomized, crossover, equivalency design was used. The parameters of interest were the percentage of patients who reported efficacy in response to FEIBA and the percentage that reported efficacy in response to NovoSeven. A difference in these percentages of no more than 15% was determined to be a clinically acceptable magnitude for equivalence of the 2 products. The primary outcome was evaluation 6 hours after treatment. Data for 96 bleeding episodes contributed by 48 participants were analyzed. The criterion for declaring the 2 products equivalent at 6 hours was not met; however, the confidence interval of the difference in percentages of efficacy reported for each product only slightly exceeded the 15% boundary (-11.4%-15.7%), P=.059. FEIBA and NovoSeven appear to exhibit a similar effect on joint bleeds, although the efficacy between products is rated differently by a substantial proportion of patients. This trial was registered at www.clinicaltrials.gov as #NCT00166309.
3.
  •  
4.
  • Berntorp, Erik (författare)
  • Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors.
  • 2009
  • Ingår i: Haemophilia. - Federation of European Neuroscience Societies and Blackwell Publishing Ltd. - 1351-8216. ; 15, s. 41343-41343
  • Tidskriftsartikel (refereegranskat)abstract
    • Summary. The bypassing agents factor eight inhibitor bypassing activity (FEIBA) anti-inhibitor coagulant complex and recombinant activated factor VII (rFVIIa) have been established as safe and effective therapies for treating bleeding episodes in haemophilia patients with inhibitors. However, the efficacy of each bypassing agent can vary, and neither agent is universally effective. The reasons for such variability have yet to be confirmed, but may involve patient-specific factors and the mechanisms of action (MOAs) and pharmacokinetic profiles of these two agents. This issue underscores the necessity of both products in the comprehensive care of patients with haemophilia and inhibitors. The objective of this review is to discuss the evidence of a differential haemostatic response to bypassing agents and the potential roles of MOA and patient-specific factors in contributing to the differences in response.
  •  
5.
  • Berntorp, Erik (författare)
  • Erik von Willebrand.
  • 2007
  • Ingår i: Thrombosis Research. - Elsevier. - 1879-2472. ; 120, s. 3-4
  • Tidskriftsartikel (refereegranskat)
  •  
6.
  • Berntorp, Erik (författare)
  • Haemate P/Humate-P: a systematic review.
  • 2009
  • Ingår i: Thrombosis Research. - Elsevier. - 1879-2472. ; 124 Suppl 1:Nov, s. 11-14
  • Tidskriftsartikel (refereegranskat)abstract
    • Haemate P/Humate-P, the first plasma-derived von Willebrand factor (VWF)/factor VIII (FVIII)-containing concentrate that was pasteurized to reduce the risk of virus infection, was developed in the 1970s and approved for use in Germany in 1981. Today, Haemate P is marketed in over 35 countries worldwide for on-demand treatment and long-term prophylaxis in patients with von Willebrand disease (VWD) or haemophilia A. With more than 25 years of clinical experience, Haemate P has demonstrated predictable pharmacokinetics, consistent haemostatic efficacy, and an excellent safety profile in paediatric and adult populations. Its VWF composition is quantitatively and qualitatively similar to that of normal plasma. The risk of virus transmission has been minimized, and treatment-related adverse events are rare. Only a very low incidence of thromboembolic events has been reported. Guidelines for dosing have been developed; optimal dosing depends on the goals of therapy, clinical setting, VWD type and severity, and other patient-related factors. Based on the extensive clinical experience with Haemate P, it has become the gold standard for replacement therapy in patients with VWD. Further studies will continue to explore its use in other clinical settings, including as immune tolerance induction therapy for patients with haemophilia A.
  •  
7.
  •  
8.
  •  
9.
  • Berntorp, Erik, et al. (författare)
  • Inhibitor treatment in haemophilas A and B: Summary statement for the 2006 International Consensus Conference
  • 2006
  • Ingår i: Haemophilia. - Federation of European Neuroscience Societies and Blackwell Publishing Ltd. - 1351-8216. ; 12, s. 41281-41281
  • Tidskriftsartikel (refereegranskat)abstract
    • Participants in an international conference on the management of haemophilia patients with inhibitors developed a jointly authored summary of the findings and conclusions of the conference. Current knowledge of the genetic and immunologic mechanisms underlying inhibitor development was briefly summarized. Concerning the purported treatment-related risk factors, conference participants commented on the limitations of the available evidence and the need for more rigorous prospective research in a fully genotyped population. Other clinical considerations discussed included the unproved utility of routine surveillance, the need for assay standardization, the management of acute bleeding and approaches to joint disease prophylaxis and immune tolerance induction (ITI). A number of issues were identified as needing further investigation in larger prospective studies, ideally through international cooperation. Such studies should enrol cohorts that have been scrupulously defined in terms of mutation status and treatment exposure. Finally, conference participants urged their colleagues to participate in the currently ongoing international trials of ITI.
10.
  • Berntorp, Erik (författare)
  • Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens.
  • 2009
  • Ingår i: Haemophilia. - Federation of European Neuroscience Societies and Blackwell Publishing Ltd. - 1351-8216. ; 15, s. 1219-1227
  • Tidskriftsartikel (refereegranskat)abstract
    • In patients with severe haemophilia, spontaneous bleeding into joints initiates a sequence of events culminating in disabling arthropathy. Early evidence from Sweden suggested that clotting factor prophylaxis improved patient outcomes. Recent randomized, controlled trials comparing prophylaxis with on-demand treatment have definitively shown that prophylaxis reduces bleeding and improves joint outcomes in patients with severe haemophilia A. Available evidence also supports the effectiveness of prophylaxis in patients with haemophilia B. In the United States, fewer than half of all patients with severe haemophilia A or B are treated with prophylaxis, and in those receiving such treatment, adherence to prophylactic treatment regimens is low in many age groups. Barriers to prophylaxis include cost, difficulties associated with venous access and the time required for prophylactic infusions. Although concerns around adherence play an important role in the willingness of physicians to prescribe prophylaxis, individualized prophylactic regimens may help increase patient adherence. Clotting factors that are more convenient and less time-consuming to infuse also may improve adherence to prophylactic therapy. By promoting rigorous adherence to prophylactic clotting factor therapies, physicians may be able to help preserve joint function in patients with severe haemophilia.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 48
 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy